Alex Adjei, MD, PhD, FACP
Chairman Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Douglas Adkins, MD
Professor of Medicine, Director, Section of Head and Neck and Thyroid Medical Oncology, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
Nasser Altorki, MD
Professor of Cardiothoracic Surgery, Director, Division of Thoracic Surgery, Weill Cornell Medical College, New York, NY
Haniel A. Araujo, MD
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Arya Adjei, MD
Associate Professor Chief of Thoracic Radiotherapy, City of Hope National Cancer Center, Department of Radiation Oncology, Duarte, CA
Leah M. Backhus, MD, MPH, FACS
Thelma and Henry Doelger, Professor of Cardiovascular Surgery, Director, Faculty Development, Associate Program Director, Thoracic Surgery Residency Program Department of Cardiothoracic Surgery, Stanford University, Stanford CA
Ani S. Balmanoukian, MD
Director of Thoracic Oncology at The Angeles Clinic and Research Institute,
a Cedars-Sinai Affiliate, Tarzana, CA
Dhruv Bansal, MD, MBA
Assistant Professor, Northshore, Department of Medicine, University of Chicago,
Chicago, IL
George R. Blumenschein, MD
Professor of Medicine, Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Julie Brahmer, MD, MSc
Professor of Oncology, Co-Director of the Upper Aerodigestive Department, Co-Director, Cancer Immunology Program, Director, Thoracic Oncology, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD
Jeremy Paul Cetnar, MD, MSHPR
Associate Professor, Knight Cancer Institute Oregon Health & Science University, Portland, OR
Joseph M. Chan, MD, PhD
Assistant Attending Physician, Department of Medicine, Thoracic Oncology Service, Assistant Member, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
Alberto Chiappori, MD
Senior Member of Oncology and Medicine, Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Jeffrey Melson Clarke, MD
Associate Professor of Medicine, Member of the Duke Cancer Institute, Department of Medicine, Duke University School of Medicine, Durham, NC
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology), Professor (By courtesy), Otolaryngology (Head and Neck Surgery), Professor (By courtesy), Radiation Oncology - Radiation Therapy, Stanford University, Stanford, CA
Angelica D’Aiello, MD
Assistant Professor of Oncology Montefiore Medical Park at Eastchester 1695 Eastchester Road, Bronx, NY
Millie (Roy) Das, MD
Clinical Professor, Department of Medicine, Stanford University School of Medicine, Stanford CA
Jonathan Dowell, MD
Professor, UT Southwestern Medical Center Hematology/ Oncology Division, Dallas, TX
Yasir Y. Elamin, MD
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Shirish Madhav Gadgeel, MD
Chief of Division of Hematology & Oncology Associate Director, Medical Oncology, Henry Ford Cancer Institute, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI
Christine A. Garcia, MD, MPH
Assistant Professor of Medicine, Director of Hematology & Oncology Fellowship Program, Director of Quality and Patient Safety, Thoracic Oncology & Benign Hematology Division of Hematology and Medical Oncology
Weill Cornell Medicine, New York, NY
Maura L. Gillison, MD, PhD
Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Ramaswamy Govindan, MD
Professor of Medicine, Anheuser Busch, Chair in Medical Oncology, Director, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, MO
Robert I. Haddad, MD
Chief, Division of Head and Neck Oncology McGraw Chair in Head and Neck Oncology Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute,
Boston MA
Nasser Hanna, MD
Professor of Medicine, Department of Medicine, Division of Hematology/
Oncology, Indiana University School of Medicine, Indianapolis, IN
Eric Haura, MD
Associate Clinical Director, Clinical Science Senior Member, Department of Thoracic Oncology & Drug Discovery, Moffitt Cancer Center, Tampa, FL
John Heymach, MD, PhD
Chair; Professor David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Fred R. Hirsch, MD, PhD, FASCO
Professor in Medicine, Icahn School of Medicine, Executive Director, Center for Thoracic Oncology, Associate Director, Tisch Cancer Institute, Mount Sinai Health System, New York, NY
Chris Holsinger, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery, Stanford University, Affiliated Faculty, Center for Artificial Intelligence in Medicine and Imaging, Member, Stanford Cancer Institute, Palo Alto, CA
Robert Hsu, MD
Assistant Professor of Clinical Medicine, Department of Internal Medicine, Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA
Puneeth Iyengar, MD, PhD
Director, Metastatic Program, Department of Radiation Oncology Memorial Sloan Kettering Cancer Center, New York, NY
Nagla Abdel Karim, MD, PhD
Director of Phase I Program Inova Schar Cancer Institute, Professor of Medicine, University of Virginia, Vienna, VA
Michael J. Kelley, MD
Professor of Medicine Member of the Duke Cancer Institute, Duke University,
Durham, NC
Hari B. Keshava, MD, MS, FACS
Assistant Clinical Professor of Surgery, Thoracic Surgery, Division of Thoracic Surgery, Department of Surgery, University of California, Irvine - School of Medicine, Orange, CA
Chul Kim, MD
Associate Professor, Georgetown University, Attending Physician, MedStar Georgetown, University Hospital, Washington, DC
Mark Klein, MD
Staff Physician, Section of Hematology/Oncology Minneapolis VA Healthcare System, Associate Professor, Division of Hematology, Oncology and Transplantation, University of Minnesota, Twin Cities, Minneapolis, MN
Robert Kratzke, MD
Professor of Medicine, John Skoglund, Chair in Lung Cancer, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN
Corey J. Langer, MD, FACP
Director of Thoracic Oncology, Abramson Cancer Center, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Xiuning Le, MD, PhD
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Lead Medical Oncologist, Clinical Investigator, Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Professor, Department of Medicine, University of Toronto, Toronto, ON
Patricia LoRusso, DO
Amy and Joseph Perella Professor of Medicine (Medical Oncology), Chief, Experimental Therapeutics Associate Cancer Center Director, Experimental Therapeutics, Yale Cancer Center, Yale University, New Haven, CT
Gilberto de Lima Lopes Junior, MD, MBA, FASCO
Professor of Clinical Medicine, Medical Director for International Programs, Associate Director for the Cancer Center, Chief, Division of Medical Oncology Sylvester Comprehensive Cancer Center, University of Miami and the Miller School of Medicine, Miami, FL
Jyoti Malhotra, MD, MPH
Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope Cancer Center, Duarte, CA
Jennifer Marks, MD
Instructor in Medicine, Harvard Medical School, Affiliate Staff, Brigham and Women’s Hospital, Medical Oncologist, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Boston, MA
Nitin Ohri, MD, MS
Professor, Radiation Oncology Montefiore Einstein, Bronx, NY
Kelsey Pan, MD, MPH Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
Cathleen Park, MD Assistant Clinical Professor (Thoracic Oncology), Division of Hematology/Oncology University of California Irvine Health, Orange, CA
Sandip P. Patel, MD
Professor, Member Thoracic Oncology, Cancer Immunotherapy Programs, Department of Medicine, Division of Hematology/Oncology, UC San Diego Moores Cancer Center, La Jolla, CA
Shetal A. Patel, MD, PhD
Assistant Professor, Division of Oncology, University of North Carolina at Chapel Hill, Lineberger, Comprehensive Cancer Center, Chapel Hill, NC
Carolyn J. Presley, MD, MHS
Associate Professor with Tenure Section, Chief, Thoracic Medical Oncology, Thoracic Oncology/Geriatric Oncology, Co-Director of the Cancer and Aging Resiliency (CARE) Clinic, Associate Medical Director of the Oncogeriatrics Program, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital/Solove Research Institute, Columbus, OH
Suresh Ramalingam, MD, FACP, FASCO
Professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished, Chair for Cancer Research, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
Jonathan W. Riess, MD, MS
Associate Professor, Director, Thoracic Oncology, Division of Hematology and Oncology, Medical Director of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA
Cristina P. Rodriguez, MD
Professor, Division of Hematology and Oncology, University of Washington Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Anjali Rohatgi, MD, PhD
Assistant Professor, Medicine, Division of Internal Medicine, Section of Medical Oncology, Washington University,
St. Louis, MO
Logan N. Roof, MD, MS
Assistant Professor, Thoracic Medical Oncology, The Ohio State University Comprehensive Cancer Center,
Columbus, OH
Samuel S. Rosner, MD
Assistant Professor of Medicine, Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD
Julia Rotow, MD
Medical Oncologist, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Nabil Saba, MD, FACP
Professor and Vice Chair for Quality and Safety, Department of Hematology and Medical Oncology, Emory University School of Medicine, Co-Director, Head and Neck Cancer Multidisciplinary Program, Winship Cancer Institute of Emory University,
Atlanta, GA
Joshua K. Sabari, MD
Assistant Professor, Department of Medicine, NYU Grossman School of Medicine, NYU Langone Health Director, High Reliability Organization Initiative Perlmutter Cancer Center, New York, NY
Jacob Sands, MD
Assistant Professor, Medicine,
Harvard Medical School Physician, Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
Ashish Saxena, MD, PhD
Associate Professor of Clinical Medicine, Weill Cornell Medical College, New York, NY
Jaime Schneider, MD, PhD
Attending Physician, Center for Thoracic Cancers, MGH Cancer Center Assistant in Medicine, Massachusetts General Hospital Instructor in Medicine, Harvard Medical School, Boston, MA
Kasmintan (Intan) Schrader, MBBS, FRCPC, PhD, DABMG
Assistant Professor, Department of Medical Genetics, The University of British Columbia, Program Medical, Co-Director, Hereditary
Cancer BC Cancer, Vancouver, BC, Canada
Eric Kumar Singhi, MD
Assistant Professor, General Oncology Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Ferdinandos Skoulidis, MD, PhD, MRCP
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Fangdi Sun, MD
Fellow, Hematology & Medical Oncology, Stanford University School of Medicine, Stanford, CA
Ming Sound Tsao, MD, FRCPC, FRSC, FCAHS
Senior Scientist and Consultant Thoracic Pathologist, University Health Network, Princess Margaret Cancer Centre, Professor of Laboratory Medicine and Pathobiology,
Professor of Medical Biophysics, University of Toronto, Toronto, ON
Dipesh Uprety, MD FACP
Assistant Professor Thoracic Oncology Karmanos Cancer Institute, Detroit, MI
Rajwanth Veluswamy, MD
Associate Professor of Medicine, Perlmutter Cancer Center, NYU Langone Health, New York, NY
Heather Wakelee, MD, FASCO
Winston Chen and Phyllis Huang Professor, Professor of Medicine/Chief-Division of Oncology, Stanford University School of Medicine, Deputy Director, Stanford Cancer Institute, Past President, International, Association for the Study of Lung Cancer (IASLC), Stanford, CA
Frank Weinberg, MD, PhD
Assistant Professor, Department of Medicine, Division of Hematology and Oncology, University of Illinois College of Medicine, Chicago, IL
Francis Paul Worden, MD
Clinical Professor, Endocrine Oncology Clinic, Roger Cancer Center, University of Michigan Health, Ann Arbor, MI
John Wrangle, MD, MPH
Associate Professor, MUSC Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, Stanford, CA
Evan Wu, MD, PhD
Director of Thoracic Oncology,
Hawaii Pacific Health, Assistant Professor, Translational and Clinical Research Program, University of Hawaii Cancer Center,
Hawaii, HI
Dan Paul Zandberg, MD
Associate Professor of Medicine and Otolaryngology, Director of Clinical Affairs, Division of Hematology/Oncology, Director, Head and Neck and Thyroid Cancer Disease Sections, Division of Hematology/Oncology, Medical Oncology Co-Leader of the Head and Neck Cancer Program, UPMC Hillman Cancer Center, Pittsburgh, PA
Jianjun Zhang, MD, PhD
Professor, Department of Thoracic/Head and Neck Medical Oncology, Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Katherine I. Zhou, MD, PhD
Medical Oncology Fellow, PGY-5, Duke University, Durham, NCKatherine I. Zhou, MD, PhD Medical Oncology Fellow, PGY-5, Duke University, Durham, NC
Alex Adjei, MD, PhD, FACP
Chairman Cleveland Clinic Taussig, Cancer Institute, Cleveland, OH
Alex Adjei, MD, PhD, is the new Chair of Cleveland Clinic Taussig Cancer Institute. Previously, he served as Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Adjei also oversaw oncology drug development, as well as lung cancer research and treatment across various Mayo Clinic sites. Additionally, he co-led the developmental therapeutics program at Mayo Clinic Cancer Center. Throughout his career, Dr. Adjei has focused his research on experimental therapeutics, regulatory science, and clinical drug development. His other research interests include health disparities, global oncology, new drug treatments for lung cancer, and the varying effects of drug toxicities. A multidisciplinary team of clinical and translational researchers under Dr. Adjei’s leadership has evaluated new drug therapies for solid tumors and hematologic malignancies.
Douglas Adkins, MD
Professor of Medicine, Director, Section of Head and Neck and Thyroid Medical Oncology, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
Dr. Douglas Adkins is Professor of Medicine at Division of Medical Oncology, Washington University School of Medicine. He graduated from Wright State University School of Medicine and completed his residency in Internal Medicine and fellowship in Medical Oncology/Hematology from University of Texas Health Sciences Center. Dr. Adkins focuses his practice on treatment of head and neck cancer and thyroid cancer. His work is focused on targeted therapy and immunotherapy in the treatment of head and neck cancer and thyroid cancer. He is actively involved in a number of prospective trials involving targeted therapy and immunotherapy in head and neck squamous cell carcinoma.
Nasser Altorki, MD
Professor of Cardiothoracic Surgery, Director, Division of Thoracic Surgery, Weill Cornell Medical College, New York, NY
Nasser Altorki, MD, is a Professor of Cardiothoracic Surgery and the Director of the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center. Following medical school in Cairo, Egypt, Dr. Altorki completed his residency in general surgery at the University of Chicago Hospital, where he subsequently completed a fellowship in Thoracic and Cardiovascular Surgery. Upon completion of his fellowship, Dr. Altorki began his hospital and teaching appointments at the Weill Cornell Medical College of Cornell University. Dr. Altorki is a renowned thoracic surgeon to students and colleagues who are particularly interested in esophageal and lung cancer surgery and research. His professional interests include: lung cancer immunotherapy and prevention; esophageal diseases, such as gastroesophageal reflux and the etiology of esophageal motor disorders; the biology, staging and therapy for esophageal carcinoma; new clinical trials in cancer; mediastinal tumors; thymomas and clinical trials in lung and esophageal cancer. His surgical interests focus on minimally invasive surgery for lung and esophageal diseases. Dr. Altorki is a member of several medical societies that focus on thoracic and cardiac surgery, as well as cancer and gastro-esophageal research and disease prevention. He has published a number of journal articles, book chapters and manuscript reviews on these topics.
Haniel A. Araujo, MD
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Haniel Araujo is Assistant Professor at the Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center. He completed his MD, Residency in Internal Medicine and Fellowship in Medical Oncology from Universidade de São Paulo. He then did Clinical Fellowship in Thoracic and Head and Neck Medical Oncology. Dr. Araujo has research interest in understanding mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant non-small cell lung cancer.
Arya Adjei, MD
Associate Professor, Chief of Thoracic Radiotherapy, City of Hope, National Cancer Center, Department of Radiation Oncology, Duarte, CA
Dr. Arya Amini is an Associate Professor in the Department of Radiation Oncology and Chief of Thoracic Radiotherapy at City of Hope with the responsibility of leading the main center and community network in up to date treatment management and research in lung, skin and head and neck cancer. He has multiple leadership responsibilities at national cooperative groups and societies including ASTRO, SWOG, and ACR. His research has led to over 200 published manuscripts in peer-reviewed journals and has several ongoing trials in lung cancer with the support of multiple grants.Arya Adjei, MD Associate Professor Chief of Thoracic Radiotherapy City of Hope National Cancer Center Department of Radiation Oncology Duarte, California Dr. Arya Amini is an Associate Professor in the Department of Radiation Oncology and Chief of Thoracic Radiotherapy at City of Hope with the responsibility of leading the main center and community network in up to date treatment management and research in lung, skin and head and neck cancer. He has multiple leadership responsibilities at national cooperative groups and societies including ASTRO, SWOG, and ACR. His research has led to over 200 published manuscripts in peer-reviewed journals and has several ongoing trials in lung cancer with the support of multiple grants.
Leah M. Backhus, MD, MPH, FACS
Thelma and Henry Doelger, Professor of Cardiovascular, Surgery Director, Faculty Development, Associate Program Director, Thoracic Surgery Residency Program, Department of Cardiothoracic Surgery, Stanford University,
Stanford, CA
Leah Backhus MD MPH FACS is the Thelma and Henry Doelger Professor in the Department of Cardiothoracic Surgery at Stanford University. She trained in general surgery at the University of Southern California and cardiothoracic surgery at the University of California Los Angeles. She practices at Stanford Hospital and is Chief of Thoracic Surgery at the VA Palo Alto. Her surgical practice consists of general thoracic surgery with special emphasis on thoracic oncology and minimally invasive surgical techniques. She heads up the Thoracic Surgical Health Services Research group in the Division of Thoracic Surgery, and has grant funding through the Veterans Affairs Administration with a VA Merit Award and is Co-PI on an NIH RO1 translational study examining diaphragm dysfunction among esophagectomy patients. She is a Charter Member Reviewer for Imaging Guided Interventions and Surgery (IGIS) study section in the NIH. Her current research interests are in cancer surveillance and survivorship care in evaluating needs, quality of life, and adherence to national standards of care. She is a member of the National Lung Cancer Roundtable of the American Cancer Society and has served as a professional member of the Patient Centered Outcomes Research Institute (PCORI) Advisory Panel on Improving Healthcare Systems. She is a member of the American Association for Thoracic Surgery and sits on the Board of Directors of the Society of Thoracic Surgeons (STS). As an educator, Dr. Backhus is the Associate Program Director for the Stanford Thoracic Track Residency program and prior Chair of the ACGME Review Committee for Thoracic Surgery. She is also the recipient of national awards in teaching by the Thoracic Surgery Residents Association and excellence in her field with the STS Extraordinary Women in Cardiothoracic Surgery Award.
Ani S. Balmanoukian, MD
Director of Thoracic Oncology at The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Tarzana, CA
Dr. Ani Balmanoukian leads the Lung Cancer Clinical Program at The Angeles Clinic and Research Institute. She received her medical degree from New York Medical College. She completed a residency in internal medicine at Johns Hopkins Hospital. She subsequently completed fellowship in hematology and medical oncology at Johns Hopkins Hospital. Dr. Balmanoukian is board certified in internal medicine, hematology and medical oncology. Dr. Balmanoukian’s clinical areas of research include novel targeted agents, immunotherapeutics, and early drug development. Her extensive experience and expertise has enhanced our patients' experience in the Phase One Program ensuring that throughout her time here our patients have been able to benefit first from major breakthroughs in recent cancer research. Dr. Balmanoukian has led the charge in Immuno-Oncology for Lung Cancers. These include work with PD-1, PD-L1 and CTLA-4 antibodies. Dr. Balmanoukian has presented data at prestigious medical meetings and has had publications in New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology. Dr. Balmanoukian is committed to excellence in comprehensive health care for patients and believes strongly in promoting care through state-of-the-art therapy while always ensuring compassionate care.
Dhruv Bansal, MD, MBA
Assistant Professor, Northshore Department of Medicine, University of Chicago, Chicago, IL
Dr. Ani Balmanoukian leads the Lung Cancer Clinical Program at The Angeles Clinic and Research Institute. She received her medical degree from New York Medical College. She completed a residency in internal medicine at Johns Hopkins Hospital. She subsequently completed fellowship in hematology and medical oncology at Johns Hopkins Hospital. Dr. Balmanoukian is board certified in internal medicine, hematology and medical oncology. Dr. Balmanoukian’s clinical areas of research include novel targeted agents, immunotherapeutics, and early drug development. Her extensive experience and expertise has enhanced our patients' experience in the Phase One Program ensuring that throughout her time here our patients have been able to benefit first from major breakthroughs in recent cancer research. Dr. Balmanoukian has led the charge in Immuno-Oncology for Lung Cancers. These include work with PD-1, PD-L1 and CTLA-4 antibodies. Dr. Balmanoukian has presented data at prestigious medical meetings and has had publications in New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology. Dr. Balmanoukian is committed to excellence in comprehensive health care for patients and believes strongly in promoting care through state-of-the-art therapy while always ensuring compassionate care.
George R. Blumenschein, MD
Professor of Medicine, Department of Thoracic-Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Ani Balmanoukian leads the Lung Cancer Clinical Program at The Angeles Clinic and Research Institute. She received her medical degree from New York Medical College. She completed a residency in internal medicine at Johns Hopkins Hospital. She subsequently completed fellowship in hematology and medical oncology at Johns Hopkins Hospital. Dr. Balmanoukian is board certified in internal medicine, hematology and medical oncology. Dr. Balmanoukian’s clinical areas of research include novel targeted agents, immunotherapeutics, and early drug development. Her extensive experience and expertise has enhanced our patients' experience in the Phase One Program ensuring that throughout her time here our patients have been able to benefit first from major breakthroughs in recent cancer research. Dr. Balmanoukian has led the charge in Immuno-Oncology for Lung Cancers. These include work with PD-1, PD-L1 and CTLA-4 antibodies. Dr. Balmanoukian has presented data at prestigious medical meetings and has had publications in New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology. Dr. Balmanoukian is committed to excellence in comprehensive health care for patients and believes strongly in promoting care through state-of-the-art therapy while always ensuring compassionate care.
Julie Brahmer, MD, MSc
Professor of Oncology, Co-Director of the Upper Aerodigestive Department, Co-Director, Cancer Immunology Program, Director, Thoracic Oncology, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, Baltimore, MD
Julie R. Brahmer, MD, MSc is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer’s research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation.
Jeremy Paul Cetnar, MD, MSHPR
Associate Professor, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
Dr. Jeremy Paul Cetnar is a medical oncologist at the Knight Cancer Institute, OHSU Health, and the OHSU School of Medicine. In addition, he is an Associate Professor at the OHSU School of Medicine and a member of the Knight Cancer Translational Oncology Program. Dr. Cetnar earned his medical degree at Loyola University Chicago Stretch School of Medicine, then completed his internship and residency in Internal Medicine at Oregon Health and Science University. He completed a fellowship in Hematology and Medical Oncology at the University of Pennsylvania Health System and then completed Master of Science in Health Policy Research at the University of Pennsylvania School of Medicine. Dr. Cetnar is the program leader of the OHSU Hematology and Medical Oncology Fellowship Program and a member of the American Society of Clinical Oncology. His care of lung cancer patients begins with advanced testing and molecular analysis to pinpoint patients’ lung cancer type, then create a treatment plan that may include a combination of radiation therapy, chemotherapy, immunotherapy, or surgery. He also treats patients with malignant pleural mesothelioma and has participated in professional panels discussing the most innovative options for this rare and challenging disease.Jeremy Paul Cetnar, MD, MSHPR Associate Professor Knight Cancer Institute Oregon Health & Science University Portland, Oregon Dr. Jeremy Paul Cetnar is a medical oncologist at the Knight Cancer Institute, OHSU Health, and the OHSU School of Medicine. In addition, he is an Associate Professor at the OHSU School of Medicine and a member of the Knight Cancer Translational Oncology Program. Dr. Cetnar earned his medical degree at Loyola University Chicago Stretch School of Medicine, then completed his internship and residency in Internal Medicine at Oregon Health and Science University. He completed a fellowship in Hematology and Medical Oncology at the University of Pennsylvania Health System and then completed Master of Science in Health Policy Research at the University of Pennsylvania School of Medicine. Dr. Cetnar is the program leader of the OHSU Hematology and Medical Oncology Fellowship Program and a member of the American Society of Clinical Oncology. His care of lung cancer patients begins with advanced testing and molecular analysis to pinpoint patients’ lung cancer type, then create a treatment plan that may include a combination of radiation therapy, chemotherapy, immunotherapy, or surgery. He also treats patients with malignant pleural mesothelioma and has participated in professional panels discussing the most innovative options for this rare and challenging disease.
Joseph M. Chan, MD, PhD
Assistant Attending Physician, Department of Medicine, Thoracic Oncology Service, Assistant Member, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
Dr. Chan is a physician scientist, thoracic oncologist, and computational biologist who is an Assistant Member at the Human Oncology and Pathogenesis Program (HOPP) and Department of Medicine at MSKCC. He received a BS from Stanford University and an MD/PhD at Columbia University, followed by internal medicine residency at Weill Cornell Medical Center and medical oncology fellowship at MSKCC. During his MD/PhD, he first became interested in developing computational methods to study how rewiring genomic information promotes rapid evolution. These efforts led to the development of a method to detect oncogenic gene fusions in glioblastoma, including FGFR-TACC fusions that were later found to be recurrent across multiple tumor types, including cholangiocarcinoma and bladder cancer where FGFR inhibition is now standard of care. He also developed a method using algebraic topology to model horizontal evolutionary events in viruses, one of the first cases of topological data analysis applied to biology. His interest in studying evolutionary rewiring of genomes across lineages ultimately seeded his postdoctoral interest in studying lineage plasticity across lung and prostate cancer as a mechanism of acquired resistance. As part of the Human Tumor Atlas Network, he constructed an atlas of SCLC and characterized intratumoral transcriptional tumor subtypes in the context of the surrounding microevironment, including a recurrent, pro-metastatic PLCG2-high SCLC state associated with pro-fibrotic macrophages. He also developed methods to quantify plasticity during the early stages of neuroendocrine transformation in prostate cancer and identified highly correlated gene programs that represent molecular drivers of this process. This strategy implicated FGFR & JAK/STAT inflammation, where combined FGFR and JAK inhibition reversed the early stages of tumor plasticity and restored sensitivity to androgen inhibition. Now, Dr. Chan leads a multidisciplinary lab developing machine learning methods leveraging single-cell and cell-free technologies to understand the epigenetic and environmental determinants of plasticity across lung, prostate, colon, and other tumor primaries, with a particular interest in histological transformation. His work has garnered multiple grants and awards, including the NCI K08 Mentored Clinical Scientist Research Career Development Award; the Conquer Cancer ASCO Harborside Endowed Merit, Young Investigator, and Career Development Awards; the ASCI Young Physician-Scientist Award; ALA Cancer Discovery Award; Concern Foundation Conquer Cancer Now Grant; and the Druckenmiller Lung Center Grant.
Alberto Chiappori, MD
Senior Member of Oncology and Medicine, Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Alberto A. Chiappori, MD currently serves as Senior Member of Oncology and Medicine for the Thoracic Oncology Program at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He has been a member of the Thoracic Oncology Program at Moffitt since 2001. Dr. Chiappori received his MD from the Universidad Peruana Cayetano Heredia in Lima, Peru. After graduation, he completed his residency at Southern Illinois University School of Medicine in Springfield, Illinois. He then went on to finish his fellowship and senior fellowship in medical oncology-hematology at Vanderbilt University School of Medicine in Nashville, Tennessee. Dr. Chiappori has been Board Certified in Medical Oncology since 1997. Dr. Chiappori has coauthored numerous articles in journals including Clinical Cancer Research, Journal of Thoracic Oncology, and Journal of Clinical Oncology. He is also an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer (IASLC).
Jeffrey Melson Clarke, MD
Associate Professor of Medicine, Member of the Duke Cancer Institute, Department of Medicine, Duke University School of Medicine, Durham, NC
Dr. Jeffrey Melson Clarke is an esteemed medical oncologist specializing in pleural mesothelioma and lung cancer. He serves as an Associate Professor of Medicine at Duke University School of Medicine and is a member of the Duke Cancer Institute. Dr. Clarke earned his medical degree from Indiana University School of Medicine and completed his residency and fellowship at Duke University Medical Center. At Duke Cancer Center, his clinical focus is on thoracic cancers, including lung cancer and mesothelioma.Jeffrey Melson Clarke, MD Associate Professor of Medicine Member of the Duke Cancer Institute Department of Medicine, Duke University School of Medicine Durham, NC Dr. Jeffrey Melson Clarke is an esteemed medical oncologist specializing in pleural mesothelioma and lung cancer. He serves as an Associate Professor of Medicine at Duke University School of Medicine and is a member of the Duke Cancer Institute. Dr. Clarke earned his medical degree from Indiana University School of Medicine and completed his residency and fellowship at Duke University Medical Center. At Duke Cancer Center, his clinical focus is on thoracic cancers, including lung cancer and mesothelioma.
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology), Professor (By courtesy), Otolaryngology (Head and Neck Surgery), Professor (By courtesy), Radiation Oncology - Radiation Therapy, Stanford University, Stanford, CA
Dr. A. Dimitrios Colevas is Professor of Medical Oncology and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy) at Stanford University. He graduated from Johns Hopkins University School of Medicine and completed his residency in Internal Medicine from Johns Hopkins University School of Medicine and fellowship in Hematology/Oncology from Dana-Farber Cancer Institute. Dr. Colevas is a medical oncologist specializing in head and neck cancers, with a focus on developing new therapeutic strategies and evaluating treatment-related toxicities. His research encompasses developmental therapeutics, investigational new drugs, and the combined use of chemotherapy and radiation therapy, particularly in treating thyroid cancer. Notably, he has led clinical trials investigating novel treatments for Epstein-Barr Virus-positive nasopharyngeal carcinoma, including the first-in-human study of the drug VK-2019.
Angelica D'Aiello, MD
Assistant Professor of Oncology, Montefiore Medical Park at Eastchester, 1695 Eastchester Road, Bronx, NY
Dr. Angelica D’Aiello serves as Assistant Professor of Oncology at Montefiore Einstein. She graduated from Stony Brook University Health Sciences Center School of Medicine and completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology in Montefiore Medical Center/Albert Einstein College of Medicine. Dr. D’Aiello’s clinical interest lies in neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer.
Millie (Roy) Das, MD
Clinical Professor, Department of Medicine, Stanford University School of Medicine, Stanford CA
Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. In 2023, she was elected President the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford.
Jonathan Dowell, MD
Professor, UT Southwestern Medical Center Hematology/ Oncology Division, Dallas, TX
Jonathan Dowell, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern, and a member of the Division of Hematology and Oncology. He also serves as Chief of Hematology/Oncology at the Dallas VA Medical Center. Dr. Dowell specializes primarily in thoracic malignancies, including non-small cell and small cell lung cancers, mesothelioma, and thymoma. Dr. Dowell earned his bachelor’s degree in neuroscience from Amherst College in Massachusetts, where he graduated magna cum laude. He received his medical degree from the University of Chicago’s Pritzker School of Medicine and completed internal medicine residency training at UT Southwestern Medical Center. He then completed advanced training through a fellowship in hematology and oncology at Vanderbilt University in Nashville. Certified by the American Board of Internal Medicine in hematology and in oncology, Dr, Dowell joined the UT Southwestern faculty in 2000. Dr. Dowell’s research interests include thoracic malignancies. His investigations have resulted in over 50 publications in peer-reviewed journals and contributions to more than 50 book chapters, reviews, editorials, and case reports. Additionally, he has presented his findings at scientific conferences throughout the United States and internationally. At UT Southwestern, Dr. Dowell chairs the Simmons Cancer Center Data and Safety Monitoring Committee and serves as the PI for the VISN 17 Veterans Affairs Lung Cancer Precision Oncology Program.
Yasir Y. Elamin, MD
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Yasir Elamin serves as Assistant Professor at the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. He completed his clinical residency in Internal Medicine from Galway University Hospital, Galway and his multiple clinical fellowships in Medical Oncology from St. James’s University Hospital, Dublin, Beaumont Hospital, Dublin and MD Anderson Cancer Center. Dr. Elamin’s research is focused on oncogene addicted lung cancer. He is a recipient of ASCO Young Investigator Award and Career Development Award.
Shirish Gadgeel, MD
Chief, Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI
Dr. Gadgeel is the Vice-Chief of Division of Hematology/Oncology for Academics at Henry Ford Health. He is also Professor of Internal Medicine at Michigan State University. After graduating with his MBBS medical degree from the University of Bombay in Mumbai, India, he completed his Internal Medicine residency in Mumbai. He also completed residency in Internal Medicine as well as his Hematology/Oncology residency at Wayne State University, in Detroit, MI. Following his fellowship, Dr. Gadgeel served as director of the Thoracic Oncology Program and co-leader of Molecular Therapeutics Program at Karmanos Cancer Institute. Prior to Henry Ford, Dr. Gadgeel was a professor in the Department of Internal Medicine and the Mary Lou Kennedy Research Professor in Thoracic Oncology at the University of Michigan/Michigan Medicine. He is the principal investigator on numerous clinical trials, and has published extensively in peer-reviewed literature, with over 200 publications. His clinical research experience spans 20 years. He is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals, including Clinical Cancer Research, Journal of Clinical Oncology, Lancet Oncology, and Journal of Thoracic Oncology. He has served as faculty for the annual meeting of the American Society of Clinical Oncology (ASCO) and as a member of the education committee of ASCO. He is a member of the Communications committee of the International Association of Study of Lung Cancer (IASLC). He was awarded by the National Cancer Institute the Cancer Clinical Investigator Team Leadership Award in 2012.
Christine A. Garcia, MD, MPH
Assistant Professor of Medicine, Director of Hematology & Oncology Fellowship Program, Director of Quality and Patient Safety Thoracic Oncology & Benign Hematology, Division of Hematology and Medical Oncology, Weill Cornell Medicine New York, NY
Dr. Christine Garcia is an oncologist and hematologist at Weill Cornell Medicine, specializing in lung cancer care. Her approach centers on empowering patients with compassionate, personalized treatment, ensuring they are well-supported and informed about their health. She is particularly focused on advancing care for EGFR-mutated lung cancer and improving patient outcomes. She also serves as the Director of Quality and Patient Safety and Chair of the Oncology Quality and Patient Safety Committee, leading initiatives that prioritize patient-centered care and safety. She is graduate of the Weill Cornell Medicine Quality Improvement Academy (QIA) and the American Society of Clinical Oncology (ASCO) Quality Training Program, serving as a mentor for trainees and faculty for quality initiatives. In addition to her clinical work, Dr. Garcia is committed to training the next generation of oncologists and hematologists. As Fellowship Program Director at Weill Cornell Medicine, she has expanded the program size and fosters a supportive learning environment. As a Weill Cornell Diversity Center of Excellence Faculty Scholar in Health Equity and an American Society of Clinical Oncology Educational Scholar, she integrates learning science principles into curriculum development, equipping her trainees with essential skills for excellence in patient care and research. She was inducted into the Weill Cornell Institute for Health Equity and Advocacy Leaders (I-HEAL) and serves as a mentor for faculty scholar projects in health equity. Dr. Garcia received her undergraduate degree from the University of Illinois at Urbana-Champaign, an M.P.H. from the University of Illinois at Chicago, and her medical degree with Distinction in Research from St. George’s University. She completed her residency at Stony Brook University Hospital and her fellowship at the University of Pittsburgh Medical Center. Outside of her professional achievements, Dr. Garcia values the support of her family, including her husband, Nick; daughter, Brett; and their Shetland sheepdog, Meeko. She enjoys cooking, yoga, art and volunteering in her free time.
Maura L. Gillison, MD, PhD
Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Maura Gillison is the Professor of Medicine at the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center. She graduated from Johns Hopkins University School of Medicine and completed Clinical Residency from Massachusetts General Hospital and Clinical Fellowship from the Johns Hopkins Oncology Center. Her laboratory focuses on the role of human papillomavirus (HPV) infection in head and neck malignancies. Her work ranges from cohort studies of oral HPV infection to genetic indicators of response to chemoradiotherapy. She is a physician scientist and has made significant contributions to the identification of human papillomavirus as a cause of a distinct subset of head and neck cancer, resulting in a paradigm shift in concepts for risk, diagnosis and therapy of head and neck cancer. As a doctorate-level trained molecular epidemiologist and medical oncologist with expertise in head and neck cancer, she currently investigates the implications of our findings for primary and secondary prevention strategies, diagnostics, prognostics, genomics, molecular therapeutics, clinical decision making and population-level cancer incidence trends in the United States and worldwide.
Ramaswamy Govindan, MD
Professor of Medicine Anheuser Busch, Chair in Medical Oncology, Director, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, MO
Dr. Ramaswamy Govindan is the Director of the Section of Medical Oncology at Washington University School of Medicine in St Louis. As a medical oncologist interested in thoracic malignancies, Dr. Govindan has led a number of institutional and multi- center phase II and III studies in lung cancer over the past decade. Working with The McDonnell Genome Institute at the Washington University School of Medicine and with The Cancer Genome Atlas (TCGA) project (as a co-chair) sponsored by the U.S. National Cancer Institute (NCI), he is actively involved in sequencing the whole genomes and exomes of several hundred patients with lung cancer. He led the group that has recently discovered mechanisms of resistance for chemotherapy in small cell lung cancer. Ongoing work led by him on the genomic alterations in primary and the corresponding brain metastases from patients with lung cancer is expected to provide new insights into how cancer cells metastasize. Dr. Govindan is the Principal Investigator for the NCI funded ALCHEMIST trial to study the role of erlotinib in patients with early-stage EGFR mutated lung cancer. Dr. Govindan is keen on translating genomic discoveries from the laboratory setting to clinical setting to improve the outcomes of patients with lung cancer. Dr. Govindan leads the effort to develop biomarkers in early-stage NSCLC using comprehensive genomic and proteomic analyses. His research is supported by multiple grants from the NCI. He has published over 370 peer- reviewed papers in scientific journals.
Robert I. Haddad, MD
Chief, Division of Head and Neck Oncology, McGraw Chair in Head and Neck Oncology, Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston MA
Robert I. Haddad, MD, is Professor of Medicine, Harvard Medical School, He is the Division Chief and Institute Physician, Center of Head and Neck Oncology Program, and a member of the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dr. Haddad received his medical degree from Saint Joseph University, French Faculty of Medicine, and served as intern and resident at St. Luke’s Roosevelt Hospital Center, New York, New York. He completed his fellowship in hematology/oncology at Greenbaum Cancer Center, University of Maryland, Baltimore, Maryland. Dr. Haddad is a member of several professional societies, including the American Society of Clinical Oncology, American Association for Cancer Research and the American Society for Therapeutic Radiology and Oncology. Dr Haddad research is focused on identifying innovative forms of treatment in Head and Neck Cancer. His research activities involve the use of induction chemotherapy for patients with locally advanced head and neck cancer and the development of novel immunotherapeutic agents for treating locally advanced disease. He has been instrumental in the development, execution and publication of numerous phase II and III trials in head and neck cancer. These trials have advanced the field of head and neck oncology and have resulted in new therapies for patients. Dr Haddad is also involved in teaching oncology fellows as well as medical residents, and ENT residents through the Dana-Farber Cancer Institute outpatient clinic and Brigham and Women’s Hospital inpatient service. He lectures extensively on head and neck cancer at the local, regional, national and international levels and has been invited to lecture in prestigious institutions and at national and international forums. He has presented his work at important scientific meetings such as the American Society of Clinical Oncology (ASCO) and the American Head and Neck Society Meeting (AHNS) and has edited two textbooks on head and neck cancer. Dr Haddad has an active role in the national comprehensive cancer network (NCCN) where he participates as a committee member in the head and neck committee and chair of the thyroid cancer committee. In this capacity, He helps write treatment guidelines. He has authored more than 200 publications related to Head and Neck cancer.
Nasser Hanna, MD
Professor of Medicine Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN
Dr. Nasser Hanna has scientific interest is primarily in thoracic oncology. He serves as the Medical Director for the Thoracic Oncology Program, which includes a multi-disciplinary group of surgeons, radiation oncologists, medical oncologists, and pulmonologists. He has led over 20 investigator-initiated trials, primarily in the area of lung cancer research. The highlights of his research include the study of consolidation docetaxel in patients with stage III non-small cell lung cancer (NSCLC) and the study of consolidation pembrolizumab in patients with stage III NSCLC. He also led the initial efforts of studying Nintedanib and Cetuximab in NSCLC. His current research focus includes the study of immunotherapy in stage III NSCLC, including combination immunotherapy in unresectable stage III disease, adjuvant immunotherapy in stage I-III surgically resected disease, and chemoradiation plus immunotherapy followed by surgery in stage III respectable NSCLC. These studies include evaluating various biomarkers to predict response/resistance and detection of minimal residual disease.
Eric Haura, MD
Associate Clinical Director, Clinical Science, Senior Member, Department of Thoracic Oncology & Drug Discovery, Moffitt Cancer Center, Tampa, FL
Dr. Eric Haura is a Thoracic Medical Oncologist with a laboratory-based research program in signal transduction, cancer proteomics, and experimental therapeutics. He received his M.D. from Duke University in 1994. He completed internal medicine residency at the Johns Hopkins Hospital in 1997 and completed fellowship training in Hematology & Oncology at Duke in 2000. He joined the H. Lee Moffitt Cancer Center and Research Institute in the Department of Thoracic Oncology in 2000 and is currently a Senior Member. He is the Director of the Moffitt Lung Cancer Center of Excellence. He is currently the Associate Center Director for Clinical Science. Dr. Haura’s major contribution has been as a leader in advancing the field of translational cancer proteomics and molecular characterization of cancers using highly integrative mass spectrometry-based proteomics. He has characterized protein architectures that regulate tumor growth and response to therapy. He developed approaches to discern mechanisms of complex drugs in cancer allowing repurposing of drugs and expanded uses. He has published more than 200 papers in top-tier scientific journals including Science Signaling, Nature Chemical Biology, Proceedings of the National Academy of Sciences, Molecular Systems Biology, Journal of Clinical Oncology, and Cancer Research. He has received numerous grants through the National Cancer Institute, industry partners, and private foundations.
John Heymach, MD, PhD
Chair; Professor, David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck, Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Heymach is the Chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. He holds the David Bruton Endowed Chair in Cancer Research. He received his undergraduate degree from Harvard University and his MD/PhD from Stanford. He completed his Internship and Residency at Brigham and Women’s Hospital and his fellowship in Medical Oncology from the Dana Farber/Mass General Brigham program. As a physician-scientist, Dr. Heymach’s research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for targeted agents and immunotherapy. His research has led to new therapeutic approaches for KRAS mutant lung cancer, small cell lung cancer (SCLC), EGFR mutant non-small cell lung cancer (NSCLC), adenoid cystic carcinoma, and oligometastatic NSCLC, many of which are now considered standard of care regimens or undergoing clinical testing. He serves as PI on 4 R01 awards investigating molecular subsets of lung cancer, and on an U01 focused on SCLC. He serves as the MDACC PI for the SU2C-ACS Lung Cancer Dream Team targeting KRAS mutant lung cancers, as the leader of the Lung CCSG Program, and the co-leader of the Lung Cancer Moon Shot. He is also the co-PI and project leader of the Lung SPORE. As a clinical investigator, he leads a number of biomarker-directed clinical trials using targeted and immunotherapy agents in lung cancer. He has directly mentored numerous fellows, including physician-scientists, and serves as chair of the NCI Molecular Cancer Therapeutics-1 study section.
Fred R. Hirsch, MD, PhD, FASCO
Professor in Medicine, Icahn School of Medicine. Executive Director, Center for Thoracic Oncology, Associate Director, Tisch Cancer Institute, Mount Sinai Health System, New York, NY
Fred R. Hirsch, MD, PhD, is Executive Director at the Center for Thoracic Oncology and Co-Director of the Center of Excellence for Thoracic Oncology at The Tisch Cancer Institute at Mount Sinai (TCI), and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He is also Associate Director of Biomarker Discovery for TCI. Dr. Hirsch has received a number of awards and honors, including the IASLC Mary Matthews Award for Translational Research in Lung Cancer in 2007; the Japanese Lung Cancer Society Merit Award in 2010; the Addario Foundation Lecture Award in 2015; and the Wuan Ki Hong Lectureship Award in 2019. Dr. Hirsch has contributed to more than 400 publications in peer-reviewed journals. He is an internationally renowned authority on lung cancer treatment and research. Dr. Hirsch’s career in lung cancer research spans more than 25 years and includes translational research, targeted therapies, and early detection of lung cancer. His research has helped identify and validate prognostic markers for lung cancer outcomes and biomarkers for personalized lung cancer therapies that illustrate how these therapies work and who is most likely to benefit from them.
Chris Holsinger, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery, Stanford University, Affiliated Faculty, Center for Artificial Intelligence in Medicine and Imaging, Member, Stanford Cancer Institute, Palo Alto, CA
Dr. Chris Holsinger is Professor of Head and Neck Surgery at Stanford University. He received his medical degree from Vanderbilt School of Medicine, completed his internship and residency at Baylor College of Medicine and his Fellowship in head and neck surgical oncology at The University of Texas M. D. Anderson Cancer Center. Dr. Holsinger’s research focuses on surgical innovation, AI, and clinical trials. He serves as surgical principal investigator for RTOG920 and coordinated surgeon-credentialing for ECOG 3311, a prospective clinical trial to study robotic head and neck surgery. Dr. Holsinger’s surgical practice focuses on the surgical management of thyroid as well as head and neck cancer. His areas of research interest include endoscopic head and neck surgery, including transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery and supracricoid partial laryngectomy.
Robert Hsu, MD
Assistant Professor of Clinical Medicine, Department of Internal Medicine, Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA
Dr. Robert Hsu is an Assistant Professor of Medicine in the Division of Medical Oncology at University of Southern California. His research interests are focused on lung cancer research along with cancer disparities across multiple solid tumor types. His research includes projects involving analysis of comprehensive genomic profiling of novel biomarkers in lung cancer, retrospective database work characterizing the lung cancer population treated at USC in Hispanic and young lung cancer patients, epidemiological research studying risk factors and mortality trends in lung and thyroid cancer incorporating the California Cancer Registry, and translational research studying the immune tumor microenvironment. Dr. Hsu was part of the IASLC Academy in 2024 and a recipient of the Robert A. Winn Excellence in Clinical Trials Career Development Award, a program focused on improving diversity in clinical trials.
Puneeth Iyengar, MD, PhD
Director, Metastatic Program, Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York, NY Director, Metastatic Program, Department of Radiation Oncology Memorial Sloan Kettering Cancer Center, New York, NY
Dr. Puneeth Iyengar works as Director (Metastatic Program) at the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. He received his MD, PhD degrees at Albert Einstein College of Medicine (NYC), following which he completed his residency in Radiation Oncology at MD Anderson Cancer Center. Dr. Iyengar’s clinical focus is on investigating the use of local therapy (SBRT) in the setting of oligometastatic NSCLC (Iyengar et al, JCO 2014, Iyengar et al, JAMA Oncology 2017), hypofractionated therapies for stage III NSCLC (Iyengar et al, JAMA Oncology 2021). He is principal investigator of NRG LU 002, a phase III randomized trial assessing the benefits of immunotherapy -/+ local therapy on overall survival for stage IV NSCLC. Dr. Iyengar also runs an independent NIH-funded research laboratory studying cancer cachexia from a basic science and translational perspective.
Nagla Abdel Karim, MD, PhD
Director of Phase I Program, Inova Schar Cancer Institute, Professor of Medicine, University of Virginia, Vienna, VA
Dr. Nagla Abdel Karim received her Medical degree from the University of Cairo- Faculty of Medicine. She subsequently received her training in Internal Medicine/Medical Oncology at the National Cancer Institute-The University of Cairo and she obtained her Masters of Science degree followed by PhD, where the latter was through a channel program with the University of Washington. She did a year of Post-doctoral fellowship at MD Anderson in Cancer Prevention, followed by one-year Research fellowship at The University of Washington. She did a residency in Internal Medicine at Fairview-Cleveland Clinic Hospitals in Cleveland, Ohio followed by a 3-year clinical fellowship in Hematology/Oncology at The University of Cincinnati then became Assistant Professor of Medicine at Ohio State University then re-joined the University of Cincinnati again in September 2011 as an Assistant Professor then Associate Professor till 2018. She has been the Professor of Medicine- Division of Hematology/Oncology and the Director of the Thoracic Oncology at the Medical College of Georgia-Augusta- Georgia since 2018 till 2022, Subsequently was the Director of the Phase I Program at Inova Schar Cancer Institute and Professor of Medicine-University of Virginia. Dr. Karim’s clinical and research interests are focused on Phase I clinical trials and the personalized approach of therapy for lung cancer. She has been the study chair of S1929 clinical trial at SWOG that focuses on personalized therapy for SLFN11 small cell lung cancer and currently works on developing and supporting to develop more concepts. She leads the thoracic neuroendocrine subcommittee within the Lung Cancer Working Group at SWOG and leads the oligometastatic subcommittee at IASLC. During all that time, she was an Investigator and Co- investigators of several Clinical Trials as well as a lead investigator on several translational research projects.
Michael J. Kelley, MD
Professor of Medicine, Member of the Duke Cancer Institute, Duke University, Durham, NC
Michael J Kelley, MD, FACP, is a Professor of Medicine at Duke University School of Medicine and the Chief of Hematology-Oncology at Durham VA Medical Center in Durham, NC. As the National Program Director for Oncology in the Department of Veterans Affairs, Dr Kelley directs policy and program development that affects more than 50,000 Veterans diagnosed with cancer each year in the nation's largest integrated healthcare system. He earned his medical degree from the University of Michigan in Ann Arbor before completing his internal medicine residency at Duke University Medical Center and a research fellowship with the Navy Medical Oncology Branch, National Cancer Institute in Washington, DC. Dr. Kelley’s clinical practice is focused on lung cancer and precision oncology while his academic interests center on molecular genetics, experimental therapeutics of targeted therapies, and outcomes research. Dr Kelley has authored more than 130 peer-reviewed research articles as well as reviews, book chapters, and meeting abstracts. He is the recipient of the US Public Health Service's Achievement Award, a member of the National Cancer Institute's Clinical Trials and Translational Research Advisory Committee and an ex officio member of the National Cancer Advisory Board. Dr Kelley is a Fellow of the American College of Physicians, and a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
Hari B. Keshava, MD, MS, FACS
Assistant Clinical Professor of Surgery, Thoracic Surgery, Division of Thoracic Surgery, Department of Surgery, University of California, Irvine - School of Medicine, Orange, CA
Dr. Iyengar is an Associate Professor and Chief of Thoracic Radiation Oncology at UT Southwestern Medical Center. He is also Vice Chair for Strategic Initiatives for the Department of Radiation Oncology and Co-Leader of the Thoracic Program at UTSW. He has led programs investigating the use of local therapy (SBRT) in the setting of oligometastatic NSCLC (Iyengar et al, JCO 2014, Iyengar et al, JAMA Oncology 2017), hypofractionated therapies for stage III NSCLC (Iyengar et al, JAMA Oncology 2021) and is principal investigator of NRG LU 002, a phase III randomized trial assessing the benefits of immunotherapy -/+ local therapy on overall survival for stage IV NSCLC. Dr. Iyengar also runs an independent NIH-funded research laboratory studying cancer cachexia from a basic science and translational perspective. Dr. Iyengar trained at MD Anderson Cancer Center and received his MD, PhD degrees at Albert Einstein College of Medicine (NYC) and Bachelor of Science at MIT.
Chul Kim, MD
Associate Professor, Georgetown University, Attending Physician, MedStar Georgetown University Hospital, Washington, DC
Dr. Chul Kim is an Associate Professor at Georgetown University with a focus on thoracic oncology. His goal as a thoracic medical oncologist is to introduce innovative cancer therapies into clinical practice, and he is devoted to formulating clinical trials aimed at promoting personalized cancer treatments. Dr. Kim's academic journey began at the Sungkyunkwan University School of Medicine in Seoul, South Korea, where he graduated Summa Cum Laude. He furthered his studies at the Harvard School of Public Health, obtaining a Master’s degree in Public Health. His medical training continued at the University of Minnesota where he trained in internal medicine. Later, he became a clinical fellow in hematology and oncology at the National Cancer Institute (NCI) of the National Institutes of Health (NIH). In 2018, Dr. Kim was honored with the Norman Rales Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). In 2021, he received the John F. Potter, MD, Award from Georgetown Lombardi Comprehensive Cancer Center. Dr. Kim has authored more than 60 articles in reputable peer-reviewed journals, including Lancet Oncology, JAMA Oncology, Journal of Thoracic Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. Additionally, he has served as a reviewer for various journals such as Journal of Clinical Oncology, Clinical Lung Cancer, Lancet HIV, Lancet Haematology, and JCO Precision Oncology. He is an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
Mark Klein, MD
Staff Physician, Section of Hematology/Oncology, Minneapolis VA Healthcare System, Associate Professor, Division of Hematology, Oncology and Transplantation, University of Minnesota, Twin Cities, Minneapolis, MN
Dr. Klein is currently a Staff Physician at the Hematology/Oncology Section at the Minneapolis VA Healthcare System and an Associate Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. He earned his medical degree at the University of Iowa. Dr. Klein then completed residency training in internal medicine and fellowship training in hematology and oncology at the University of Minnesota. His laboratory research interests include basic research in mesothelioma, and his clinical and translational research interests include lung cancer and head and neck cancer. He is currently involved in the Veterans Affairs Lung Cancer Precision Oncology Program grant and the NCI Alliance for Clinical Trials Oncology Cooperative Group.
Robert Kratzke, MD
Professor of Medicine, John Skoglund Chair in Lung Cancer, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN
Dr. Kratzke graduated from the University of Washington School of Medicine in 1983 and completed his residency training in Internal Medicine at the University of Wisconsin Hospital and Clinics in 1986. Between 1986 and 1988, he did research at the McArdle Laboratory for Cancer Research at the University of Wisconsin Madison in the laboratory of Dr. Jeff Ross. He was a Medical Oncology Fellow at the National Cancer Institute (NCI) of the National Institutes of Health from 1988 to 1991, and stayed at the NCI doing research with Dr Frederick Kaye until 1994. From 1993 through 1994, Dr. Kratzke was also an Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. From 1994 to 2004, he was a Staff Physician at the Minneapolis VA Medical Center in the Section of Hematology/Oncology. He has spent his entire career in translational mesothelioma and lung cancer research beginning during his fellowship at the NCI-Navy Medical Oncology Branch (John Minna, Director). Based on his accomplishments in 2004 he was awarded the John Skoglund Chair for Lung Cancer Research at the University of Minnesota. In recent years he has redirected his research interests to projects involving oncolytic virotherapy and improving response to immunotherapy for lung cancer or mesothelioma therapy.
Corey J. Langer, MD, FACP
Director of Thoracic Oncology, Abramson Cancer Center ,Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Dr. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987. Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC. He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects. Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). Since 2016, he has been Editor-in-Chief of the International Lung Cancer News (ILCN) under the aegis of the IASLC. For the past 34 years, since completing his fellowship, Professor Langer has led or co-led over 140 clinical trials in both small cell (SCLC) and non-small cell lung cancer (NSCLC), as well as mesothelioma and head and neck cancer. Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 270 peer-reviewed papers.
Xiuning Le, MD, PhD
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
As Assistant Professor in the Thoracic/Head and Neck department Dr. Le has contributed her knowledge via trials, clinical journals and lectures with focus non-small cell lung cancer with actionable oncogenes. Le earned her medical degree from the Peking Union Medical College. She then went on to earn a degree in Biological and Biomedical Sciences at Harvard Medical School in Boston. She completed her internship and residency at The University of Massachusetts Medical Center in Worcester, MA, an additional residency at the University of Texas. Prior to joining the staff at M.D. Anderson, she also completed a fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Board certified in both internal medicine and medical oncology, Dr. Le specializes in thoracic, head, and neck oncology. Dr. Le has published more than 40 articles in the field of lung and head and neck cancer. She was first- or last author of many high-impact papers, including New England Journal of Medicine, Cancer Discovery, Clinical Cancer Research and Journal of Thoracic Oncology. Just recently Dr. Le received the ASCO Young Investigator Award, SU2C-TVF Convergence Program, Claudia Adams Barr for Innovative Cancer Research, ASCO Career Development Award, Paul Calabresi NIH K12 Award and more.
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Lead Medical Oncologist, Clinician Investigator, Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Professor Department of Medicine, University of Toronto, Toronto, ON
Dr. Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. After receiving her MD from the University of Toronto, Canada, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed her fellowship in thoracic oncology at the Princess Margaret Hospital, Canada and a fellowship in clinical oncology at the University of Sydney, Australia. She received her Masters in Medical Science (MMSc) in clinical epidemiology at the University of Newcastle, Australia. Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 WCLC, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, a member of the IASLC Quality and Value Committee, on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation.
Patricia LoRusso, DO
Amy and Joseph Perella Professor of Medicine (Medical Oncology), Chief, Experimental Therapeutics, Associate Cancer Center Director, Experimental Therapeutics, Yale Cancer Center, Yale University, New Haven, CT
Dr Patricia LoRusso is Professor of Medicine (Medical Oncology), Yale University/Yale Cancer Center. She has expertise in testing new treatments on patient volunteers who have advanced stages of cancer. She graduated from Michigan State University and completed her residency in Internal Medicine from Riverside Osteopathic Hospital and fellowship in Hematology and Medical Oncology from Wayne State University. As the associate director of experimental therapeutics at Yale Cancer Center, Dr. LoRusso is a nationally recognized expert in developing new cancer drugs through clinical trials. Dr. LoRusso has pioneered significant advances in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.
Jyoti Malhotra, MD, MPH
Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Cancer Center,
Duarte, CA
Jyoti Malhotra, MD is an Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. She is a thoracic medical oncologist and a member of the Developmental Therapeutics program. Dr. Malhotra’s expertise is in Experimental Therapeutics and she has led multiple phase I trials investigating novel agents and combinations for cancer therapy including first-in-human trials. Dr. Malhotra has a particular interest in novel approaches to combine immunotherapy with other agents for the treatment of lung cancer and refractory solid tumors. Dr. Malhotra has led multiple investigator-initiated clinical trials as well as a national trial sponsored by the National Cancer Institute- Cancer Therapy Evaluation Program (CTEP). She is also an active member of the SWOG cooperative group and serves on the NCCN panel for small cell lung cancer. Dr. Malhotra completed her residency in Internal Medicine at Georgetown University Hospital and Washington Hospital Center in Washington, DC and her fellowship in Hematology and Oncology at Mount Sinai Hospital in New York City.
Jennifer Marks, MD
Instructor in Medicine, Harvard Medical School Affiliate Staff, Brigham and Women’s Hospital, Medical Oncologist, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Boston, MA
Jennifer A. Marks, MD is a Thoracic Medical Oncologist at Dana-Farber Cancer Institute and Brigham and Women's Hospital and an Instructor in Medicine at Harvard Medical School. She received her medical degree from Tulane University School of Medicine in New Orleans, LA. She completed her internship and residency in Internal Medicine at Emory University School of Medicine in Atlanta, GA, and her Medical Oncology fellowship at MedStar Georgetown University Hospital in Washington, DC. Dr. Marks’ professional interests lie in precision medicine and biomarker identification, thymic tumors, and cellular therapies in lung cancers. Her research in MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer earned her prestigious recognitions including an Early Career Education Award at the 2022 World Conference on Lung Cancer and a Conquer Cancer Merit Award at the 2023 American Society of Clinical Oncology Conference. Her recent work investigates SEZ6 expression in neuroendocrine tumors and multicomplex immunofluorescent staining in thymic epithelial tumors. She developed a clinical trial protocol studying sacituzumab govitecan in advanced thymoma and thymic carcinoma at the AACR/ASCO Methods in Clinical Research Workshop, a trial that is actively enrolling. Dr. Marks is dedicated to advancing personalized care in thoracic oncology, driving innovation through clinical and translational research, and improving patient outcomes worldwide.
Nitin Ohri, MD, MS
Professor, Radiation Oncology, Montefiore Einstein, Bronx, NY
Dr. Nitin Ohri is Professor, Radiation Oncology at Montefiore Einstein. He is a radiation oncologist with a clinical focus on treating lung and gastrointestinal cancers. Dr. Ohri earned his Doctor of Medicine from Washington University in 2007. He then completed an internship in internal medicine at Barnes-Jewish Hospital in 2008 and then participated in a radiation oncology residency at Thomas Jefferson University, completing it in 2012. Dr. Ohri earned his Master's degree from the Clinical Research Training Program at Montefiore Einstein in 2015. Dr. Ohri’s research focuses on incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy. Dr. Ohri has designed numerous ongoing and completed investigator-initiated trials that test novel functional imaging-based radiotherapy delivery strategies and new combinations of immunotherapy and radiotherapy. He is also leading a series of trials incorporating continuous activity monitoring with wearable devices into the care of cancer patients. Dr. Ohri is board certified in Radiation Oncology by the American Board of Radiology and is a member of the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Association for Cancer Research. He has won multiple awards, including numerous “Outstanding Reviewer” Awards from the International Journal of Radiation Oncology, Biology, Physics, the Cancer Care Delivery Research Pilot Project Award from NRG Oncology and the Fellowship Award from the Empire Clinical Research Investigator Program.
Kelsey Pan, MD, MPH
Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center,
Houston, TX
Dr. Kelsey Pan is Hematology/Oncology Fellow at the University of Texas MD Anderson Cancer Center. She graduated from University of Miami Miller School of Medicine and completed her Residency in Internal Medicine from University of Florida Health. Dr. Pan has research interest in understanding mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations.
Cathleen Park, MD
Assistant Clinical Professor (Thoracic Oncology), Division of Hematology/Oncology, University of California Irvine Health, Orange, CA
Cathleen Park is a board-certified Medical Oncologist with expertise in treating thoracic malignancies at the Chao Family Comprehensive Cancer Center at the University of California, Irvine. Her research interests encompass targeted therapy, early phase clinical trials, and the application of plasma-based cancer biomarkers.
Sandip P. Patel, MD
Professor, Member Thoracic Oncology, Cancer Immunotherapy Programs, Department of Medicine, Division of Hematology/Oncology UC San Diego Moores Cancer Center, La Jolla, CA
Sandip Patel, MD is a Professor at UCSD and a Medical Oncologist focusing on early phase clinical trials of immunotherapy and thoracic oncology. He is the leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD. He is co-leader of the NRG Developmental Therapeutics Committee and co-leader of the University of California Lung Cancer Consortium.
Shetal A. Patel, MD, PhD
Assistant Professor, Division of Oncology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Shetal Patel, MD, PhD, has a clinical focus in treating patients with thoracic and head/neck malignancies. Her research interests include translational studies and clinical trials to improve treatment options for patients, with a particular focus on novel immunotherapy combinations, genomic profiling, and targeted therapies. She leads the lung cancer clinical trials research group and co-leads the Precision Oncology Program at UNC Lineberger Comprehensive Cancer Center.
Carolyn J. Presley, MD MHS
Associate Professor with Tenure Section, Chief, Thoracic Medical Oncology, Thoracic Oncology/Geriatric Oncology, Co-Director of the Cancer and Aging Resiliency (CARE) Clinic Associate Medical Director of the Oncogeriatrics Program, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital/Solove Research Institute, Columbus, OH
Dr. Carolyn Presley is an Associate Professor on the tenure track in the Division of Medical Oncology/Department of Internal Medicine at The Ohio State University, Comprehensive Cancer Center and The James Cancer Hospital/Solove Research Institute. She earned her medical degree from Dartmouth Medical School and completed residency in Internal Medicine and combined fellowship in Geriatric Oncology and Hematology at Yale University. Dr. Presley is an active member of the Ohio State University Comprehensive Cancer Program, The American Geriatrics Society, and the American Society of Clinical Oncology. She has been a long-time member of the international Cancer and Aging Research Group (CARG). She currently leads studies focused on maintaining functional independence among older adults with lung cancer. These studies incorporate geriatric assessment, embedded palliative care, and interventions to improve risk factors for treatment toxicity and functional decline.
Suresh Ramalingam, MD, FACP, FASCO
Professor, Department of Hematology and Medical Oncology Roberto C. Goizueta, Distinguished Chair for Cancer Research, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer. Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar. Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.
Jonathan W. Riess, MD, MS
Associate Professor, Director, Thoracic Oncology, Division of Hematology and Oncology, Medical Director of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA
Dr. Riess is Medical Director of Thoracic Oncology. Dr. Riess' clinical interests include lung cancer and other thoracic cancers (mesothelioma and thymoma) as well as head and neck cancers. He currently serves on the Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel for the National Comprehensive Cancer Network (NCCN). Dr. Riess graduated from Robert Wood Johnson Medical College and completed his residency in Internal Medicine and fellowship in Hematology/Oncology from UC San Francisco and Stanford University School of Medicine, respectively. Dr. Riess' research interests encompass novel diagnostics, targeted therapies and immunotherapies in lung cancer and other thoracic malignancies. He is the past recipient of the National Cancer Institute Cancer Clinical Investigator Team Leadership Award given to researchers who are working to improve the lives of people with cancer through extensive involvement in NCI-funded collaborative clinical trials and whose leadership, participation and activities promote clinical trials and research. He is also the past (co)recipient of the Addario Lung Cancer Foundation and Van Auken Foundation Young Innovators Team Award.
Cristina P. Rodriguez, MD
Professor, Division of Hematology and Oncology, University of Washington Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Dr. Cristina Rodriguez is Professor at the Division of Hematology and Oncology at University of Washington and Professor at Clinical Research Division, Fred Hutchinson Cancer Center. She graduated from University of the Philippines and completed her residency in Internal Medicine and fellowship in Hematology-Oncology from Cleveland Clinic Foundation. Dr. Rodriguez researches and treats cancers of the head and neck. She leads clinical trials that explore how to incorporate targeted therapies into current treatment standards. Dr. Rodriguez has a particular interest in improving outcomes for squamous cell carcinomas of the head and neck, salivary gland cancers and thyroid cancers that no longer respond to radioactive iodine therapy. She also explores ways to reduce racial and economic disparities for these cancers, many of which involve modifiable risk factors such as smoking, alcohol and human papillomavirus infections.
Anjali Rohatgi, MD, PhD
Assistant Professor, Medicine, Division of Internal Medicine, Section of Medical Oncology, Washington University, St. Louis, MO
Dr. Anjali Rohatgi is an Assistant Professor of Medicine in the Division of Medical Oncology at Washington University. She received her MD and completed her residence in Internal Medicine from Washington University in St. Louis School of Medicine. Following which, she completed her fellowship in Hematology/Oncology from University of Pittsburgh Medical Center. Dr. Rohatgi has clinical interest in applying targeted therapies and immunotherapy to improve survival outcomes for patients with metastatic non-small cell lung cancer.
Logan N. Roof, MD, MS
Assistant Professor, Thoracic Medical Oncology, The Ohio State University Comprehensive Cancer Center,
Columbus, OH
Dr. Logan Roof is an Assistant Professor in Thoracic Medical Oncology at The Ohio State University Comprehensive Cancer Center. She graduated from Medical University of South Carolina College of Medicine and completed her residency in Internal Medicine and fellowship in Hematology/Oncology from University of Cincinnati and Cleveland Clinic Foundation, respectively. Dr. Roof’s research is focused on advancing care for patients with mesothelioma, improving immunotherapy and targeted therapy techniques, and expanding access to lung cancer screening. She specializes in thoracic malignancies including lung cancer, mesothelioma, and thymic cancers. She has a particular interest in treating patients with malignant pleural mesothelioma.
Samuel S. Rosner, MD
Assistant Professor of Medicine, Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD
Dr. Rosner is a thoracic oncologist with expertise in peri-operative clinical trial design and immunotherapeutic drug development for early and advanced non-small cell lung cancer (NSCLC). Currently, he serves as an assistant professor of medicine at the University of Maryland Marlene & Stewart Greenebaum Cancer Center. In his clinical role, he treats patients with thoracic malignancies. Prior to joining faculty at the University of Maryland, he completed his post-graduate oncology fellowship training at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC), during which time he served as Chief Oncology Fellow from 2022-2023. One of Dr. Rosner's research goals focuses on improving peri-operative outcomes for patients with early-stage non-small cell lung cancer (NSCLC). Key research efforts in this treatment space include evaluating the role of immune checkpoint blockade in the perioperative management of early-stage NSCLC, as well as assessing the surrogacy of pathologic endpoints, such as pathological complete response (pCR), in terms of long-term clinical outcomes for patients who receive neoadjuvant therapy. Dr. Rosner is also actively involved in the conception, design and implementation of early-phase clinical trials testing novel immunotherapeutic strategies for both early and advanced stage NSCLC. For his effort evaluating the immunologic responses of KRAS-mutant NSCLC, he was awarded the 2022 ASCO Young Investigator Award. In addition, his work evaluating the response of oncogene-driven NSCLC to neoadjuvant immune checkpoint blockade was recognized with an ASCO Merit award at the 2023 ASCO annual meeting. Dr. Rosner is an active member of the American Society of Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASLC).
Julia Rotow, MD
Medical Oncologist, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Dr. Rotow received her MD from the UCLA David Geffen School of Medicine. She completed her residency training in Internal Medicine at the Massachusetts General Hospital and her fellowship training in Hematology/Oncology at the University of California, San Francisco. She practices as a thoracic oncologist at the Dana-Farber Cancer Institute where she is and clinical director of the Lowe Center for Thoracic Oncology and an Assistant Professor at Harvard Medical School. Her research interests include the development of targeted therapies for the treatment of oncogene-driven lung cancer.
Nabil Saba, MD, FACP
Professor and Vice Chair for Quality and Safety, Department of Hematology and Medical Oncology, Emory University School of Medicine, Co-Director, Head and Neck Cancer Multidisciplinary Program, Winship Cancer Institute of Emory University, Atlanta, GA
Nabil F. Saba, MD, FACP, is an internationally recognized expert in the treatment of head and neck cancers. Dr. Saba is professor and vice chair in the Department of Hematology and Medical Oncology, and the Inaugural Lynne and Howard Halpern Chair in Head and Neck Cancer Research. He holds a joint appointment as professor in the Department of Otolaryngology at Emory University School of Medicine. He serves as director of the Head and Neck Cancer Medical Oncology Program and is co-leader of the Multidisciplinary Head and Neck Program at Winship Cancer Institute of Emory University. Dr. Saba earned his Medical Degree from the American University of Beirut Medical School. He completed a Residency in Internal Medicine at Tufts University School of Medicine in Boston, and a Clinical Fellowship in Hematology and Oncology at Brown University School of Medicine. He subsequently completed a Bone Marrow Transplant Fellowship at the University of Toronto Princess Margaret Hospital in Toronto, Canada. Dr. Saba is a well-recognized expert in immunotherapy for head and neck cancer and upper aero-digestive malignancies. His work is focused on translational research and the study and development of novel therapeutic agents and modalities in these diseases. He has been principal investigator in more than 50 clinical trials and chairs national as well as investigator initiated multi-institution studies focusing on novel approaches for treating head and neck and esophageal cancer. Dr Saba has been instrumental in establishing the head and neck cancer research working group at Winship Cancer Institute and is the contact principal investigator of the Lead Academic Participating Site (LAPS) grant of the NCI’s National Clinical Trials Network (NCTN).
Joshua K. Sabari, MD
Assistant Professor, Department of Medicine, NYU Grossman School of Medicine, NYU Langone Health Director, High Reliability Organization Initiative Perlmutter Cancer Center, New York, NY
Dr. Sabari is an Assistant Professor of Medicine, Thoracic Medical Oncologist and member of the Phase I Experimental Therapeutics Group in the Department of Medical Oncology at New York University School of Medicine, NYU Langone Health Perlmutter Cancer Center. Dr. Sabari’s research focus includes developing new treatments for people with lung cancers. His goal is to develop biomarker-driven clinical trials that offer patients unprecedented access to novel therapies and personalized treatments.
Jacob Sands, MD
Assistant Professor, Medicine, Harvard Medical School Physician, Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
Dr. Jacob Sands joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2017. He received his MD from the University of Cincinnati in 2005. He completed his residency in internal medicine at the University of California, Davis and fellowship training in hematology/oncology also at the University of California, Davis. His research focuses on improved diagnostics and treatments for small cell lung cancer as well as improving lung screening and assisting in the development of lung screening programs throughout the country. Dr. Sands conducts clinical trials with novel treatment options with particular focus on small cell lung cancer and antibody drug conjugates. He leads the small cell lung cancer clinical research program at DFCI and has helped develop multiple protocols for small cell lung cancer trials. His largest clinical trial is an NCI-sponsored adjuvant non-small cell lung cancer study incorporating immunotherapy either concurrent with chemotherapy or sequential after chemotherapy. Dr. Sands was a member of the committee that developed and oversaw a benchmark lung screening program that has become a model for program development throughout the country. He is a co-founder and President of the Rescue Lung Society, a 501(c)3 non-profit medical society focused on advancing lung cancer screening.
Ashish Saxena, MD, PhD
Associate Professor of Clinical Medicine, Weill Cornell Medical College, New York, NY
Dr. Saxena is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the NewYork-Presbyterian Hospital. He graduated from the Medical Scientist Training Program at Stony Brook University, receiving his MD and a PhD in Genetics. Following this he completed his residency in internal medicine at Montefiore Medical Center and fellowship in Hematology/Oncology at Weill Cornell Medical College-New York-Presbyterian Hospital. After fellowship Dr. Saxena worked as a post-doctoral research fellow at the Sloan Kettering Institute of the Memorial Sloan Kettering Cancer Center where his research focused on the study of exosomes. He returned to Weill Cornell Medical College in 2015 to join the faculty of the Division of Hematology and Medical Oncology in their Thoracic Oncology program. Dr. Saxena's clinical and research interests have been in the study and management of different forms of lung cancer. He currently treats patients with non-small cell and small-cell lung cancers, mesothelioma, thymoma, and sarcomas of the lung. He is involved in both clinical and laboratory research, collaborating with physicians and scientists at Weill Cornell as well as other institutions.
Jaime Schneider, MD, PhD
Attending Physician, Center for Thoracic Cancers, MGH Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School, Boston, MA
Dr. Jaime Schneider is a medical oncologist specializing in the care of patients with thoracic malignancies at the Massachusetts General Hospital (MGH) in Boston, MA. She is an instructor in medicine at Harvard Medical School where she uses integrative metabolomics approaches to study metabolic dependencies in lung cancer. Dr. Schneider received her MD and PhD degrees from the Albert Einstein College of Medicine and completed her residency training in Internal Medicine at MGH. Dr. Schneider then matriculated into the Hematology/Oncology fellowship program at Harvard where she trained as a medical oncologist at the Dana-Farber Cancer Institute and MGH Cancer Center. She joined the laboratory of Dr. Marcia Haigis at Harvard Medical School for her post-doctoral work to investigate mechanisms of cancer resistance through metabolic reprogramming. She is the recipient of research awards from organizations including A Breath of Hope Lung Foundation, Lung Cancer Research Foundation, ALK Positive, EGFR Resisters, American Cancer Society, AACR, and the IASLC. The primary focus of Dr. Schneider’s research is to develop novel therapeutic strategies for patients with advanced lung cancers. Her basic/translational research efforts are dedicated to the study of resistance mechanisms in molecularly defined subsets of lung cancer. The ultimate goal of her research is to improve outcomes for patients living with lung cancer.
Kasmintan (Intan) Schrader, MBBS, FRCPC, PhD, DABMG
Assistant Professor, Department of Medical Genetics, The University of British Columbia, Program Medical Co-Director, Hereditary Cancer BC Cancer, Vancouver, BC, Canada
Dr. Kasmintan Schrader works as Program Medical Co-Director at the BC Cancer agency’s Provincial Hereditary Cancer Program. She received her medical degree from the University of Melbourne (2003), and completed her residency in Medical Genetics at the University of British Columbia, Canada. Dr Schrader undertook the Royal College of Physicians and Surgeons of Canada Clinician Investigator Program to undertake graduate studies in the Department of Pathology and Laboratory Medicine to investigate the association between germline mutations in CDH1 and lobular breast cancer. Her PhD work evolved to include use of next-generation sequencing technology to identify Mendelian disease genes. She was subsequently awarded a Canadian Institutes of Health and Research training award to pursue her interests in using next-generation sequencing (NGS) technology to determine novel susceptibility genes in familial colon cancer as a research fellow at MSKCC. Dr Schrader utilized NGS to co-discover PAX5 as a novel susceptibility gene to Pre-B cell acute lymphoblastic leukemia. She has also utilized NGS to analyze DNA of multiple primary tumors in parallel with the germline DNA and successfully determined the underlying cancer susceptibility in the patient. In addition to looking for novel susceptibility genes, in view of the rapid sequencing advances in oncology, Dr. Schrader’s research involves assessing the scope and impact of incidental findings identified in the course of next generation sequencing in the research and clinical setting.
Eric Kumar Singhi, MD
Assistant Professor, General Oncology, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Eric K. Singhi is an Assistant Professor and Thoracic Medical Oncologist at the University of Texas MD Anderson Cancer Center. He completed his Internal Medicine residency at Vanderbilt University and served as Chief Hematology/Oncology fellow at MD Anderson during his training. As faculty at MD Anderson, Dr. Singhi specializes in patient education research and young onset lung cancer research. He serves as the Patient Safety and Quality Officer for the Thoracic Medical Oncology Service Line, and as Co-Director of the Thoracic Medical Oncology rotation for the MD Anderson medical oncology fellowship program.
Ferdinandos Skoulidis, MD, PhD, MRCP
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Ferdinanados Skoulidis is currently a Tenured Associate Professor (Physician Scientist) at the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. He obtained a Medical Degree from the Aristotle University of Thessaloniki, Greece in 2000 and a PhD from the University of Cambridge, UK in 2011. He completed general medicine residency and medical oncology fellowship training in Cambridge and London, UK. Dr Skoulidis’ laboratory is focused on (a) unraveling the molecular and clinical heterogeneity of KRAS-mutant non-small cell lung cancer (NSCLC) and developing novel therapeutic strategies to target KRAS-mutant lung tumors; (b) maximizing the therapeutic potential of direct KRAS inhibitors and (c) elucidating the impact of individual somatic genomic alterations on the NSCLC immune contexture and immunotherapy response, with the goal of developing novel precision oncogenotype-tailored immunotherapeutic strategies. Dr Skoulidis has received several awards for his research including a 2019 AACR NextGen Star award. His work has been published in high-impact scientific journals including The New England Journal of Medicine, Cancer Discovery, Cancer Cell, Nature Reviews Cancer and his research has attracted research funding from the NIH/NCI, the Cancer Prevention and Research Institute of Texas and the US Department of Defense.
Fangdi Sun, MD
Fellow, Hematology & Medical Oncology, Stanford University School of Medicine, Stanford, CA
Dr. Fangdi Sun is Hematology & Medical Oncology Fellow at Stanford University School of Medicine. She completed her undergraduate studies in Biological Engineering at the Massachusetts Institute of Technology, followed by her medical degree at Harvard Medical School. She then completed a residency and chief residency in Internal Medicine at the University of California, San Francisco as part of the PRIME clinical research pathway, working with Dr. Caroline McCoach to study clinical outcomes of novel tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer (NSCLC). As a fellow at Stanford, she hopes to hone her interests in thoracic oncology as a clinical trial investigator, with a focus on mechanisms of resistance to targeted therapies in NSCLC.
Ming Sound Tsao, MD, FRCPC, FRSC, FCAHS
Senior Scientist and Consultant, Thoracic Pathologist, University Health Network, Princess Margaret Cancer Centre, Professor of Laboratory Medicine and Pathobiology, Professor of Medical Biophysics, University of Toronto, Toronto, ON
Dr. Tsao is a Thoracic Pathologist and Senior Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, Professor of Laboratory Medicine and Pathobiology and Professor of Medical Biophysics at the University of Toronto. He is the current Secretary and a member of the Board of Directors, member of the Staging and Prognostic Factor Committee, and member and past Chair of the Pathology Committee of the International Association for the Study of Lung Cancer (IASLC). He has published extensively in the pathology, prognostic and predictive biomarkers, and molecular pathobiology of lung cancer. Dr. Tsao was a member of the Standing Editorial Board for the 5th Edition of the WHO Classification on Tumours, and past Chair (2006-23) of the Canadian Cancer Trials Group (CCTG) Correlative Science and Tumor Biology Committee. He is globally known as a leader in molecular testing for lung cancer and has led several multi-center projects to standardize lung cancer biomarker assays in Canada. Dr. Tsao was a recipient of the Canadian Cancer Society O. Harold Warwick Award, the IASLC Mary Matthew Pathology and Translational Research Award, and the CCTG Dr. Joseph Pater Founder’s Award for Excellence in Clinical Trials Research. He is an elected Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences.
Dipesh Uprety, MD FACP
Assistant Professor, Thoracic Oncology, Karmanos Cancer Institute, Detroit, MI
Dr. Uprety is an Assistant Professor in the Department of Medical Oncology at Karmanos Cancer Institute and specializes in the care of patients with lung cancer. He graduated from BP Koirala Institute of Health Sciences, Dharan, Nepal with a Bachelor of Medicine and Bachelor of Surgery degree. He then did an Internal Medicine residency at Abington-Jefferson Health, Abington, Pennsylvania. He was a Hematology and Medical Oncology fellow at Gundersen Health System, La Crosse, Wisconsin, where he also served as a Chief Fellow in his final year. He then did an advanced fellowship in Thoracic Oncology at Mayo Clinic, Rochester, Minnesota. Dr. Uprety is also actively involved in clinical research and has published more than 100 papers or abstracts including original research, commentaries, editorial, abstracts and a book chapter in the leading journals and major conference meetings. He has special interest on studying mechanisms of resistance to immunotherapy.
Rajwanth Veluswamy, MD
Associate Professor of Medicine, Perlmutter Cancer Center, NYU Langone Health,
New York, NY
Dr. Rajwanth Veluswamy is an Associate Professor of Medicine at Perlmutter Cancer Center - NYU Langone Health. He is a board-certified medical oncologist who specializes in the treatment of lung cancer and other thoracic malignancies. He earned his M.D. from the University of Szeged and a Masters of Science in Clinical Research at Mount Sinai. Following which, he completed residency in Internal Medicine at Methodist Dallas Medical Center, and a research internship at MD Anderson Cancer Center in Houston. He then, completed both a clinical fellowship in Hematology and Medical Oncology and a General Medicine research fellowship at the Icahn School of Medicine at Mount Sinai. Dr. Veluswamy’s research focuses on understanding the factors responsible for clinical outcomes in lung cancer patients, from patterns of care to differences in therapeutic drug efficacy. He has published extensively and presented his research at international meetings where he has received numerous merit awards. He received a prestigious ASCO Young Investigator Award in recognition and support of his research during fellowship. Dr. Veluswamy’s clinical interest is to provide personalized treatment that best fits each patient. He collaborates with a multidisciplinary team of experts and scientists that are highly active in the treatment and research of thoracic malignancies.
Heather Wakelee, MD, FASCO
Winston Chen and Phyllis Huang, Professor, Professor of Medicine/Chief-Division of Oncology, Stanford University School of Medicine, Deputy Director, Stanford Cancer Institute, Past President, International Association for the Study of Lung Cancer (IASLC), Stanford, CA
Dr. Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University, and Deputy Director of the Stanford Cancer Institute. Dr. Wakelee serves as the Past President of the International Association for the Study of Lung Cancer (IASLC) and she is a Fellow of the American Society of Clinical Oncology (FASCO). She is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed her post-graduate training at Stanford University. As an experienced lung cancer investigator, Dr. Wakelee has authored or co-authored over 300 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials involving adjuvant therapy, immunotherapy, and anti-angiogenesis agents. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others. Her translational efforts to date have involved collaborations with colleagues in medical oncology, thoracic radiation oncology, thoracic surgery, radiology, pulmonary medicine, and population sciences.
Frank Weinberg, MD, PhD
Assistant Professor, Department of Medicine, Division of Hematology and Oncology, University of Illinois College of Medicine, Chicago, IL
Frank Weinberg, MD, PhD, is a physician-researcher, Assistant Professor in the Division of Hematology and Oncology at the University of Illinois College of Medicine Chicago and a medical oncologist at UI Health focused on providing the best care for patients with lung cancer. He graduated from University of Illinois and completed his residency and fellowship from University of Michigan. In his research, Dr. Weinberg focuses on improving outcomes for patients undergoing immunotherapy, with a particular interest in advancing the understanding of cancer biology and metabolism. As a member of the University of Illinois Cancer Center, his contributions to these fields have led to important discoveries that inform clinical practice. Under his leadership, UI Health’s lung cancer immunotherapy trials are establishing new benchmarks in cancer treatment, further advancing the standard of care in this area.
Francis Paul Worden, MD
Clinical Professor, Endocrine Oncology Clinic, Roger Cancer Center, University of Michigan Health, Ann Arbor, MI
Dr Frank Worden is a Clinical Professor of Medicine at the University of Michigan Rogel Cancer Center. Dr Worden earned a degree in pharmacy and pharmaceutical sciences from Purdue University and is a graduate from the Indiana University School of Medicine. He then completed a residency in Medicine and Pediatrics at the Detroit Medical Center. Following residency, Dr Worden completed a fellowship in hematology and oncology at the University of Michigan and joined the faculty in 2000. Dr Worden is the director of the Michigan Medicine Head and Neck Clinical Research Team and lead endocrine oncologist for the Michigan Medicine Endocrine Oncology Program. He is the former fellowship program director for hematology/oncology at Michigan Medicine. In 2019, Dr Worden was named the Nancy Wigginton Endowed Chair of Thyroid Cancer Research. His clinical interests include organ preservation strategies for locally advanced, HPV-related head and neck cancers and clinical trials research for thyroid cancers.
John Wrangle, MD, MPH
Associate Professor, MUSC Hollings Cancer Center, Medical University of South Carolina,
Charleston, SC
Dr. John Wrangle is a thoracic medical oncologist who specializes in treating non-small cell and small cell lung cancer as well as other thoracic malignancies at the Medical University of South Carolina (MUSC). His medical degree was awarded by Tulane University School of Medicine. He completed a residency in internal medicine at Emory University School of Medicine, followed by fellowship training at Johns Hopkins Hospital. Dr. Wrangle is dedicated to bringing novel combination immunotherapy treatments to patient care and has developed precision medicine protocols designed to create additional options for patients so they can avoid poorly tolerated, low-efficacy chemotherapy treatment. Dr. Wrangle is actively involved in clinical trials and research examining the use of immunotherapy drugs in the treatment of lung cancer and other thoracic malignancies.
Evan Wu, MD, PhD
Director of Thoracic Oncology, Hawaii Pacific Health, Assistant Professor, Translational and Clinical Research Program, University of Hawaii Cancer Center, Hawaii, HI
Dr. Evan Wu earned his Medical Degree from the University of Miami and Ph.D. in Biostatistics from Johns Hopkins University. Dr. Wu attended Johns Hopkins School of Medicine, Division of Hematology and Oncology, where he was fellowship trained in medical oncology. Dr. Wu is a board-certified medical oncologist and clinical researcher focusing on thoracic cancers, including lung cancer and mesothelioma. Dr. Wu previously worked as a Medical Director in early oncology at AstraZeneca, where he led the development of targeted therapies for lung cancer.
Dan Paul Zandberg, MD
Associate Professor of Medicine and Otolaryngology Director of Clinical Affairs, Division of Hematology/Oncology Director, Head and Neck and Thyroid Cancer Disease Sections, Division of Hematology/Oncology Medical Oncology Co-Leader of the Head and Neck Cancer Program UPMC Hillman Cancer Center Pittsburgh, PA
Dr. Dan Zandberg is Associate Professor of Medicine and Otolaryngology at University of Pittsburgh. He also serves as Director of the Head and Neck and Thyroid Cancer Disease Sections at the Division of Hematology/Oncology at UPMC Hillman Cancer Center. He graduated from Jefferson Medical College and completed his residency in Internal Medicine and fellowship in Hematology/Oncology from George Washington University Medical Center and University of Maryland, respectively. Dr. Zandberg is a translational and clinical researcher. His primary interest is the development of novel immunotherapy trials to improve outcomes in recurrent/metastatic squamous cell carcinoma of the head and neck.
Jianjun Zhang, MD, PhD
Professor, Department of Thoracic/Head and Neck Medical Oncology, Professor, Department of Genomic Medicine Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Jianjun Zhang is Professor of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. He serves as the Chair of Lung Moon Shot GEMINI database, the Director of Lung Cancer Interception Program and Director of Lung Cancer Genomics Program. He is a physician scientist with research focusing on elucidating the impact of cancer molecular features on host anti-tumor immune surveillance during cancer evolution with or without anti- tumor therapy and the molecular mechanisms underlying the transformation of premalignancy into invasive lung cancer. His group has made critical contributions to understand the molecular evolution during early lung carcinogenesis. His group has led a series of studies that demonstrated progressive genomic/epigenomic alterations from normal lung cells to lung premalignancies, preinvasive lung cancers and invasive lung cancers accompanied by a gradually less effective and more intensively regulated immune response; driver mutations, chromosomal copy number aberrations (CNAs) and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in preneoplasia into dominant clones in invasive lung cancer; complex molecular heterogeneity is associated with impaired T cell response and inferior survival. He published >200 peer-reviewed papers in high-impact journals including Nature, Science, Cell, Lancet Oncology, Journal of Clinical Oncology, etc. His studies have led to the development of two unique clinical trials in a completely novel clinical research field: targeting tumor immune microenvironment for lung cancer prevention: IMPRINT-Lung and Can-Prevent-Lung.
Katherine I. Zhou, MD, PhD
Medical Oncology Fellow, PGY-5, Duke University, Durham, NC
Dr. Katherine I. Zhou, MD, PhD is a medical oncology fellow at Duke. She earned both her PhD in Biochemistry and Molecular Biophysics and her MD at the University of Chicago, where she studied the mRNA modification N6-methyladenosine under the mentorship of Dr. Tao Pan. She completed her residency in Internal Medicine at Duke University, where she is now in her third year of medical oncology fellowship. As a resident and fellow, she has been involved in several correlative and real-world projects aimed at identifying biomarkers of response to immune checkpoint inhibitors in advanced solid tumors, and she has studied real-world outcomes of cancer patients treated with targeted therapies in the Veterans Health Administration. Currently, she studies the role of small nucleolar RNAs in solid tumor metastasis under the mentorship of Dr. Christopher Holley at Duke and Dr. Chad Pecot at UNC.